 Home > Active Ingredient News > Immunology News > Rheumatology: Rituximab maintenance therapy after remission induction in relapsed or refractory SLE

Rheumatology: Rituximab maintenance therapy after remission induction in relapsed or refractory SLE

 Last Update: 2022-10-10
 Source: Internet
 Author: User

Tags

6 3 nm

3 4 inches

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Objective: To investigate the efficacy and safety of rituximab (RTX) maintenance therapy and traditional immunosuppressive (ISA) maintenance therapy in patients with relapsed or refractory systemic lupus erythematosus (SLE)

Methods: This study was a prospective observational nonrandomized cohort study recruiting SLE patients who received at least one course of RTX induction therapy at four centers

Patients who were clinically responsive to RTX were divided into two groups based on maintenance therapy in the first 12 months: the RTX group and the ISA group

Results: Of the 82 patients included in the cohort, 67 (81.

After a median follow-up of 24 months, a total of 13 patients (19.

Multivariate analysis identified use of hydroxychloroquine, RTX maintenance therapy, and hematologic involvement as independent predictors of sustained remission

Conclusions: This multicenter prospective cohort study demonstrates that long-term RTX maintenance therapy has high efficacy and acceptable safety in patients with relapsed or refractory SLE who are clinically responsive to RTX induction therapy

Source:

Chen X, Shi X, Xue H, et al.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Top quantity Imiquimod CAS NO 99011-02-6 White crystalline powder 99% API

CAS No.: 99011-02-6

Pharmacy Grade

$1800-1850/KG FOB

High Purity 99% BPN14770 Zatolmilast 1606974-33-7 In Stock Fast Ship to USA

CAS No.: 1606974-33-7

Pharm Grade

$1-1.1/UNIT FOB

High quality Thymosin α1 Pure CAS 62304-98-7 Thymosin Alpha 1 Thymalfasin

CAS No.: 62304-98-7

Pharmacy Grade

$12-15/UNIT FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.